Truvai Biosciences provides cutting-edge research services and specializes in providing innovative strategies aimed at overcoming immunogenicity concerns to improve patient outcomes.
We are currently developing and seek to commercialize use of our patented products (OPLS, known as TVB-628) to reduce immunogenicity for monoclonal antibodies and other therapeutic proteins for acute and chronic use.
"Courage is resistance to fear, mastery of fear, not absence of fear"
Mark Twain
Our Story
Founded by University at Buffalo faculty, Truvai Biosciences, LLC is a biotechnology company specializing in patented and cutting-edge strategies to reduce immunogenicity. We currently provide research services and are in the process of developing our patented products (OPLS, known as TVB-628) for commercialization to improve efficacy for protein therapeutics and monoclonal antibodies whose use may have previously been limited or whose development was discontinued altogether. Get in touch today to learn more.
Get in Touch
©2021 by Truvai Biosciences, LLC